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Abstract
Background: Acrylamide, a probable human carcinogen, is present in many everyday foods. Since the finding of its
presence in foods in 2002, epidemiological studies have found some suggestive associations between dietary acrylamide
exposure and the risk of various cancers. The aim of this prospective study is to investigate for the first time the association
between dietary acrylamide intake and the risk of several histological subtypes of lymphatic malignancies.
Methods: The Netherlands Cohort Study on diet and cancer includes 120,852 men and women followed-up since
September 1986. The number of person years at risk was estimated by using a random sample of participants from the total
cohort that was chosen at baseline (n = 5,000). Acrylamide intake was estimated from a food frequency questionnaire
combined with acrylamide data for Dutch foods. Hazard ratios (HRs) were calculated for acrylamide intake as a continuous
variable as well as in categories (quintiles and tertiles), for men and women separately and for never-smokers, using
multivariable-adjusted Cox proportional hazards models.
Results: After 16.3 years of follow-up, 1,233 microscopically confirmed cases of lymphatic malignancies were available for
multivariable-adjusted analysis. For multiple myeloma and follicular lymphoma, HRs for men were 1.14 (95% CI: 1.01, 1.27)
and 1.28 (95% CI: 1.03, 1.61) per 10 mg acrylamide/day increment, respectively. For never-smoking men, the HR for multiple
myeloma was 1.98 (95% CI: 1.38, 2.85). No associations were observed for women.
Conclusion: We found indications that acrylamide may increase the risk of multiple myeloma and follicular lymphoma in
men. This is the first epidemiological study to investigate the association between dietary acrylamide intake and the risk of
lymphatic malignancies, and more research into these observed associations is warranted.
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Introduction
In 2002, the scientific world was alarmed by the discovery of
acrylamide in foods by the Swedish Food Authority. Acrylamide
was classified as a proven rodent carcinogen and a probable
human carcinogen by the International Agency for Research on
Cancer in 1994, because of its carcinogenicity in rodents and
because of the similarity between the way it is metabolized in
rodents and in humans [1]. Several frequently consumed foods,
such as French fries, cookies and coffee, contain high levels of
acrylamide [2]. Acrylamide in food is formed in Maillard
browning reactions, in which amino acids, asparagine in
particular, react with reducing sugars during baking or other
thermal processing at temperatures higher than 120 degrees
Celsius. Its formation depends on various cooking variables,
particularly temperature and duration [3]. This causes large
variations in the acrylamide content of different brands of the
same food as well as among batches of a food of the same brand.
The mechanism by which acrylamide causes cancer in
laboratory animals and by which it may cause cancer in humans
is still unclear. Currently, the genotoxic action of glycidamide,
which is an epoxide metabolite of acrylamide, is taken to be the
mechanism of carcinogenic action in acrylamide risk assessments.
Ample in vitro and in vivo animal studies have shown that
acrylamide, mainly after metabolic conversion to glycidamide by
the enzyme cytochrome P4502E1 (CYP2E1), causes chromosomal
damage (aberrations, micronuclei, aneuploidy) and mutagenic
effects [4]. However, the tissues with most DNA adducts or DNA
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mutations do not consistently correspond to the tissues in which
cancer occurred in the rat studies [5,6] and, more and more, other
mechanisms of acrylamide carcinogenesis are being proposed
[7,8]. Animal studies have shown positive dose-response relations
between acrylamide intake through drinking water and cancer in
multiple organs in mice and rats, such as the mammary glands,
thyroid gland, testes and the uterus [4]. The presence of these
mainly sex hormone-related cancers in animals, suggests a
hormonal pathway [4,9,10], perhaps occurring in addition to
genotoxic effects.
Since the finding of the presence of acrylamide in foods in 2002,
epidemiological studies have evaluated various cancer endpoints in
association with dietary acrylamide exposure of humans. A
positive association for endometrial cancer was observed in two
prospective cohort studies [11,12]. Both studies found a positive
association for ovarian cancer as well, and in one of those studies
this association was strongest in serous tumours [12]. Two studies,
a cohort study and a nested case-control study, found a positive
association between dietary acrylamide intake and the risk of
estrogen receptor-positive breast cancer [13,14]. Further, a
positive association was observed with renal cancer risk [15],
and with oral cavity cancer risk in non-smoking women [16], both
in a Dutch cohort study. In a Finnish prospective cohort study, a
positive association was observed with lung cancer risk in smoking
men [17].
Some epidemiological studies found indications for inverse
associations with cancer risk, such as with lung cancer risk in
women [18], prostate cancer risk in never-smoking men, bladder
cancer risk in women [15], and oro-and hypopharyngeal cancer
risk in men [16].
Theoretically, every tissue in the human body, including
lymphoid tissues, is a target for acrylamide carcinogenesis, because
acrylamide is hydrophilic, and therefore it is able to diffuse
passively throughout the whole body [19]. During the last decades,
the occurrence of lymphatic malignancies has risen dramatically.
This type of cancer is a heterogeneous group of malignancies
derived from the T-cell and the B-cell development, and the most
common types are multiple myeloma, diffuse large cell lymphoma
and chronic lymphocytic leukemia [20]. Little is known about
modifiable risk factors for these malignancies.
In the Finnish Alpha-Tocopherol, Beta-Carotene Cancer
Prevention (ATBC) Study, no association was observed between
dietary acrylamide intake and the risk of lymphomas in male
smokers [17]. In this Finnish study, no analyses were done for
histological subtypes of lymphatic malignancies, and therefore an
association with a specific type of lymphatic malignancy might
have been missed. Our study is the first to investigate the
association between dietary acrylamide intake and the risk of
several common subtypes of lymphatic malignancies.
Methods
Ethics Statement
By returning the completed questionnaire, the participants gave
consent to participate in this study. The study protocol was
approved by the Medical Ethics Committee of the University
Table 1. Number of lymphatic malignancies in the Netherlands Cohort Study on diet and cancer (follow up: 16.3 years) according
to the WHO classification.
Lymphatic malignancies ICD-O-3 morphology codes N1 N2
T-cell, all 54
T-cell lymphoma 9701–9709, 9714 41
Mucosis fungoides 9700 20
B-cell, precursor lesions
Acute lymphocytic leukemia 9836–9837 12
Lymphoblastic lymphoma 9727–9728 8
Burkitt’s lymphoma 9687 4
B-cell, other 9826, 9832–9833 2
Malignant lymphomas, B-cell, mature neoplasms
Diffuse large-cell lymphoma (DLCL) 9675, 9680, 9684 294 259
Follicular lymphoma (FL) 9690–9698 98 91
Waldenstro¨m macroglobulinemia and immunocytoma (WMI) 9671, 9761 90 89
Mantle cell lymphoma (MCL) 9673 63 56
Extranodal marginal B-cell lymphoma or MALT 9699 21
Malignant lymphoma NOS 9590–9596 88
Chronic lymphocytic leukemia 9670, 9823 224 200
Multiple myeloma 9731–9732, 9734 363 323
Hairy cell leukemia 9940 10
Hodgkin lymphoma 9650–9669 37
Total 1,375 1,233
Abbreviations: ICD-O-3, International Classification of Diseases for Oncology, 3rd edition; MALT, mucosa-associated lymphoid tissue; NOS, not otherwise specified.
1N after exclusion of prevalent cases at baseline.
2N cases available for analyses, after exclusion of missing and inconsistent data. Only case numbers for subtypes with sufficient number of cases are given (so subgroups
do not add up to 1,233).
doi:10.1371/journal.pone.0038016.t001
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Hospital Maastricht and the Netherlands Organisation for Applied
Scientific Research (TNO), division of Nutrition.
Study Design and Population
In September 1986, 58,279 men and 62,573 women were
enrolled in the Netherlands Cohort Study on diet and cancer
(NLCS), a prospective cohort study [21]. All participants were at
the age of 55–69 years at entry. Participants were selected through
computerized municipal population registries.
Data processing and analysis were based on the case-cohort
approach for efficiency reasons. The number of cancer cases
(providing the numerator information for the estimation of cancer
incidence rates) is the number of cases in the total cohort. The
number of person-years at risk (providing the denominator
information) was estimated by using a subcohort, a random
sample of participants from the total cohort that was chosen at
baseline (n = 5,000). Subcohort members were censored when
they died, emigrated, reached the end of follow-up, or became a
case, whichever came first.
Participants in this study are considered to be a case if they had
a microscopically verified diagnosis of a lymphatic malignancy
during the 16.3 year follow-up period. Incident cases in the total
cohort were detected by annual computerized record linkages to
the Netherlands Cancer Registry and the Netherlands Pathology
Registry. The completeness of cancer follow-up through linkages
with these registries is estimated to be at least 96% [22]. The
histological subtype of the lymphatic malignancy was coded by the
Netherlands Cancer Registry, using the International Classifica-
tion of Diseases for Oncology, adapted for the Netherlands [23].
These codes were used to reclassify the lymphatic malignancies in
categories according to the WHO classification of tumours of
hematopoietic and lymphoid tissues [24]. For cases that could not
be assigned to a specific category, the summary of the pathology
report of the Netherlands Pathology Registry was inspected, and, if
possible, the case was assigned to a WHO category. Case numbers
per histological subtype of lymphatic malignancies are given in
table 1. The procedure is described elsewhere in more detail [25].
Cases and subcohort members were excluded from analysis if
they reported cancer at baseline (except for skin cancer) or if their
dietary data were incomplete or inconsistent. After 16.3 years of
follow-up (from September 1986 through December 2002), there
were 1375 cases of lymphatic malignancies, after exclusion of
aforementioned cancer cases at baseline. Dietary data was
complete and consistent for 1,277 cases, and 1,233 cases had
complete data for covariables and were included in the analysis.
Figure 1 shows the selection and exclusion steps that resulted in the
numbers of cases and subcohort members that were available for
analysis. Follow-up of the subcohort was nearly complete; only 1
male member of the subcohort was lost to follow-up.
Acrylamide Intake Assessment
Data on dietary habits and potential confounding variables were
collected at baseline by means of the NLCS food frequency
questionnaire (FFQ). The FFQ contains questions on 150 foods,
measuring frequency and portion size for most.
To estimate acrylamide intake, we used a database with
acrylamide concentrations in foods on the Dutch market, provided
by the Dutch Food and Consumer Product Safety Authority. In
2002, this authority analyzed the levels of acrylamide in various
Dutch foods, such as bread, French fries, pastry, cake and Dutch
spiced cake [26]. In 2005, the authority analyzed several foods to
specifically accommodate the estimation of acrylamide intake of
Figure 1. Flow diagram of subcohort members and cases used in the analysis. NCR = Netherlands Cancer Registry, PALGA = Netherlands
Pathology Registry, LM = lymphatic malignancies, MM = multiple myeloma, DLCL = diffuse large cell lymphoma, CLL = chronic lymphocytic
leukaemia, FL = follicular lymphoma, WMI = Waldenstrom macroglobulinemia and immunocytoma, MCL = mantle cell lymphoma, T-cell = T-cell
lymphoma.
doi:10.1371/journal.pone.0038016.g001
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Table 2. Characteristics of cases and subcohort members according to sex in the Netherlands Cohort Study on diet and cancer,
1986–2002.
Variable1 Subcohort CLL DLCL MM FL WMI MCL T-cell
Men
N 2,191 139 165 172 44 54 41 36
Dietary variables
Acrylamide intake (mg/d) 23 (12) 21 (11) 23 (13) 25 (13) 26 (16) 26 (17) 22 (10) 22 (11)
Acrylamide intake BW (mg/d per
kg bw)
0.29 (0.16) 0.28 (0.15) 0.29 (0.17) 0.33 (0.18) 0.34 (0.21) 0.33 (0.21) 0.27 (0.13) 0.29 (0.15)
Coffee (g/d) 578 (290) 576 (304) 561 (265) 547 (233) 588 (295) 545 (209) 570 (296) 601 (283)
Dutch spiced cake (g/d) 4.1 (8.6) 3.2 (6.6) 4.2 (8.4) 5.5 (9.7) 8.9 (14.2) 6.4 (13.6) 3.8 (7.4) 3.1 (7.7)
Cookies (g/d) 14 (11) 14 (9) 13 (11) 16 (18) 12 (10) 15 (10) 16 (9) 17 (10)
Potato chips (g/d) 0.47 (1.72) 0.30 (1.01) 0.59 (3.16) 0.62 (2.54) 0.21 (0.57) 0.35 (0.71) 0.59 (1.84) 0.33 (1.02)
French fries (g/d) 7.2 (15.4) 6.3 (12.8) 7.7 (19.9) 9.4 (17.9) 4.8 (8.0) 9.1 (17.1) 4.6 (11.7) 5.4 (10.5)
Total energy intake (kcal/d) 2,162 (510) 2,208 (509) 2,133 (486) 2,194 (541) 2,164 (568) 2,239 (489) 2,171 (395) 2,180 (375)
Carbohydrate (g/d) 227 (66) 229 (61) 226 (61) 232 (65) 224 (56) 238 (66) 220 (44) 232 (48)
Saturated fat (g/d) 37 (12) 39 (13) 36 (12) 37 (12) 35 (12) 37 (11) 36 (10) 37 (10)
Trans unsaturated fatty acid (g/d) 3.3 (1.7) 3.6 (1.7) 3.5 (2.0) 3.6 (1.8) 2.9 (1.3) 3.4 (1.6) 3.1 (1.5) 3.2 (1.4)
Total fatty acids (g/d) 87 (27) 91 (27) 86 (25) 90 (29) 89 (34) 87 (25) 89 (23) 88 (22)
Mono unsaturated fat (g/d) 35 (12) 38 (12) 35 (11) 37 (13) 36 (16) 36 (10) 35 (10) 36 (10)
Poly unsaturated fat (g/d) 20 (10) 19 (8) 19 (9) 21 (10) 22 (14) 19 (9) 23 (11) 20 (8)
Fiber (g/d) 29 (9) 29 (9) 28 (9) 30 (9) 29 (9) 31 (8) 30 (9) 30 (8)
Alcohol (g/d) 15 (17) 14 (16) 14 (17) 12 (13) 12 (13) 19 (22) 17 (15) 12 (13)
Niacin (g/d) 15 (5) 16 (5) 15 (4) 15 (5) 16 (6) 16 (4) 15 (4) 16 (5)
Non-dietary variables
Age (y) 61.3 (4.2) 62.1 (4.1) 62.0 (4.0) 61.8 (3.9) 61.1 (4.4) 61.8 (4.1) 62.0 (4.4) 61.1 (4.2)
BMI (kg/m2) 25.0 (2.6) 25.0 (2.4) 25.0 (2.4) 25.2 (2.7) 24.8 (2.7) 25.4 (2.3) 25.2 (2.0) 24.6 (2.6)
Height (m) 1.76 (0.07) 1.77 (0.06) 1.78 (0.07) 1.76 (0.07) 1.78 (0.08) 1.76 (0.07) 1.80 (0.06) 1.77 (0.08)
Non-occupational physical activity
(min/d)
80 (68) 84 (84) 79 (68) 80 (62) 107 (96) 66 (52) 82 (85) 79 (72)
Family history of HM (%) 2.5 5.0 4.9 2.9 9.1 3.7 7.3 0.0
Cigarette smoking
Never-smokers (%) 12.7 15.1 11.5 13.4 11.4 9.3 19.5 13.9
Former smokers (%) 51.6 55.4 47.9 59.3 38.6 59.3 58.5 41.7
Current smokers (%) 35.7 29.5 40.6 27.3 50.0 31.5 22.0 44.4
Smoking quantity (n cig./d)2 17 (11) 15 (11) 16 (10) 15 (10) 20 (12) 18 (15) 16 (11) 15 (8)
Smoking duration (y)2 34 (12) 34 (12) 34 (12) 32 (13) 35 (10) 32 (13) 33 (13) 36 (11)
Education
Primary school (%) 25.0 24.6 25.8 22.2 27.9 24.1 17.5 8.3
Lower vocational school (%) 20.7 18.1 19.6 26.3 20.9 9.3 20.0 22.2
Intermediate vocational school (%) 35.6 40.6 31.9 33.3 32.6 31.5 40.0 50.0
Higher vocational school (%) 18.7 16.7 22.7 18.1 18.6 35.2 22.5 19.4
Women
N 2247 68 104 161 49 35 18 20
Dietary variables
Acrylamide intake (mg/d) 21 (12) 20 (11) 21 (11) 21 (13) 23 (18) 23 (15) 20 (14) 27 (19)
Acrylamide intake BW (mg/d per
kg bw)
0.32 (0.19) 0.29 (0.17) 0.31 (0.17) 0.30 (0.19) 0.34 (0.26) 0.33 (0.20) 0.31 (0.25) 0.40 (0.30)
Coffee (g/d) 497 (245) 494 (241) 503 (202) 511 (234) 515 (258) 471 (285) 458 (271) 494 (172)
Dutch spiced cake (g/d) 5.7 (9.4) 4.9 (8.4) 5.4 (8.9) 5.2 (9.8) 7.9 (16.3) 8.2 (11.8) 6.1 (11.6) 10.0 (14.8)
Cookies (g/d) 14 (11) 14 (9) 14 (14) 15 (12) 13 (9) 15 (11) 14 (9) 15 (11)
Potato chips (g/d) 0.40 (1.93) 0.62 (3.15) 0.19 (0.76) 0.16 (0.46) 0.16 (0.52) 0.27 (0.94) 0.11 (0.28) 0.43 (1.08)
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the NLCS cohort, such as various types of bread, specific types of
cookies, cake and pastry, chocolate and chocolate milk, nuts and
salty snacks, peanut butter and coffee. Acrylamide was measured
in types of cookies which were known to be eaten most frequently
by a population comparable with the NLCS, as was known from
the development phase of the questionnaire. Bread was sampled
and analyzed again in 2005, because the quantitation limit of the
analytic method had decreased from 30 ppb in 2002 to 15 ppb in
2005. This change offered the opportunity to more accurately
estimate the acrylamide intake via bread. To determine the
acrylamide level for each food, the mean values of the acrylamide
measurements per food were used, or, in case the concentrations
were lower than the quantitation limit, a value one-half the
quantitation limit. This database was recently validated in a study
comparing estimated acrylamide content (using acrylamide data
from the database) and measured acrylamide content of duplicate
24-hour diets [27]. This rendered a correlation coefficient of 0.82,
which indicates that it is feasible to make a sound rank ordering of
the acrylamide intake via a 24-hour meal using the mean
acrylamide levels for individual foods in the database.
The acrylamide intake for each participant in the study was
estimated by multiplying the acrylamide level of each food with the
frequency of consumption and the portion size of that food, and
summing up these values across all foods.
Statistical Analysis
Acrylamide is included in the multivariable-adjusted models as a
continuous variable per 10 mg per day intake of acrylamide as well
as a categorical variable, to be able to investigate the dose-response
relationship, where possible. For acrylamide to be modeled as a
categorical variable, we required at least 100 cases for quintile
categories in subgroup analyses or 60 cases for tertile categories. In
case there were less than 60, but more than 20 cases in a subgroup,
we analyzed acrylamide as a continuous variable only. Following
these criteria, we thus analyzed multiple myeloma, diffuse large
cell lymphoma, chronic lymphocytic leukemia, follicular lympho-
ma, Waldenstrom macroglobulinemia and immunocytoma in
Table 2. Cont.
Variable1 Subcohort CLL DLCL MM FL WMI MCL T-cell
French fries (g/d) 4.0 (8.8) 1.7 (4.6) 3.1 (7.7) 4.0 (12.5) 2.8 (8.5) 3.4 (6.0) 1.4 (3.4) 5.7 (11.1)
Total energy intake (kcal) 1,683 (397) 1,762 (463) 1,634 (339) 1,711 (402) 1,747 (384) 1,708 (302) 1628 (370) 1,878 (468)
Carbohydrate (g/d) 179 (48) 190 (58) 174 (45) 184 (45) 183 (49) 184 (35) 165 (40) 205 (63)
Saturated fat (g/d) 30 (10) 31 (11) 30 (9) 30 (10) 32 (9) 29 (7) 29 (9) 35 (11)
Trans unsaturated fatty acid (g/d) 2.5 (1.2) 2.3 (0.9) 2.4 (0.9) 2.6 (1.3) 2.5 (0.9) 2.3 (0.9) 2.2 (0.9) 3.1 (1.4)
Total fatty acids (g/d) 69 (22) 71 (28) 68 (18) 70 (23) 70 (16) 69 (16) 70 (21) 77 (22)
Mono unsaturated fat (g/d) 28 (9) 29 (12) 27 (7) 28 (10) 28 (7) 28 (7) 29 (10) 31 (9)
Poly unsaturated fat (g/d) 15 (7) 15 (10) 15 (7) 15 (8) 14 (7) 17 (6) 16 (5) 16 (7)
Fiber (g/d) 25 (7) 26 (8) 26 (7) 27 (8) 26 (6) 27 (7) 26 (5) 26 (6)
Alcohol (g/d) 5.9 (9.5) 5.5 (9.6) 3.7 (7.2) 4.6 (7.7) 5.9 (10.7) 5.5 (8.9) 6.6 (8.5) 5.7 (8.6)
Niacin (g/d) 12 (3) 13 (5) 12 (3) 13 (4) 13 (3) 12 (3) 13 (3) 13 (3)
Non-dietary variables
Age (y) 61.4 (4.3) 62.6 (4.0) 62.0 (4.6) 62.4 (4.2) 61.9 (4.3) 62.0 (4.2) 61.6 (4.4) 60.3 (4.3)
BMI (kg/m2) 25.1 (3.6) 25.1 (4.3) 24.6 (3.3) 25.6 (3.6) 15.2 (3.6) 25.0 (3.6) 23.9 (2.7) 24.9 (3.3)
Height (m) 1.65 (0.06) 1.67 (0.07) 1.66 (0.07) 1.66 (0.06) 1.66 (0.05) 1.67 (0.05) 1.66 (0.08) 1.65 (0.07)
Non-occupational physical
activity (min/d)
64 (53) 67 (59) 62 (54) 70 (62) 62 (44) 76 (71) 69 (71) 52 (31)
Family history of HM (%) 3.2 2.9 4.8 5.6 6.1 0.0 11.1 5.0
Cigarette smoking
Never-smokers (%) 58.4 66.2 65.4 67.7 57.1 57.1 50.0 65.0
Former smokers (%) 20.6 20.6 17.3 21.1 14.2 25.7 27.8 20.0
Current smokers (%) 21.0 13.2 17.3 11.2 28.6 17.1 22.2 15.0
Smoking quantity (n cig./d)2 11 (8) 15 (12) 12 (8) 11 (8) 11(7) 11 (5) 12 (7) 8 (11)
Smoking duration (y)2 28 (13) 27 (14) 29 (11) 26 (12) 30 (11) 30 (11) 23 (14) 24 (12)
Education
Primary school (%) 33.5 29.4 35.0 34.4 27.1 34.3 22.2 35.0
Lower vocational school (%) 23.2 25.0 19.4 25.0 20.8 17.1 22.2 10.0
Intermediate vocational school (%) 34.5 38.2 39.8 34.4 43.8 40.0 44.4 45.0
Higher vocational school (%) 8.8 7.4 5.8 6.3 8.3 8.6 11.1 10.0
MM = multiple myeloma; DLCL = diffuse large cell lymphoma; CLL = chronic lymphocytic leukemia; FL = follicular lymphoma; WMI = Waldenstro¨m
macroglobulinemia and immunocytoma; MCL = mantle cell lymphoma; T-cell = T-cell lymphomas; BW = bodyweight; HM = hematological malignancies.
1Mean (standard deviation) or percentage.
2Among former or current smokers.
doi:10.1371/journal.pone.0038016.t002
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Table 3. Association between dietary acrylamide intake and the risk of multiple myeloma, diffuse large cell lymphoma, and
chronic lymphocytic leukemia according to sex and smoking status; the Netherlands Cohort Study on diet and cancer, 1986–
2002.1
Acrylamide
intake (per
10 mg/d) Q1/T1 Q2 Q3/T2 Q4 Q5/T3 P for trend
Multiple myeloma
All men
Cases/py 170/28,981 32/5,656 20/5,661 35/5,899 34/5,833 49/5,933
HR (CI 95%)2 1.15 (1.04–1.27) 1.00 (ref) 0.63 (0.36–1.13) 1.10 (0.67–1.82) 1.09 (0.66–1.82) 1.51 (0.94–2.41) 0.01
HR (CI 95%)3 1.14 (1.01–1.27) 1.00 (ref) 0.65 (0.36–1.16) 1.14 (0.67–1.94) 1.14 (0.67–1.94) 1.54 (0.92–2.58) 0.02
Never-smoking men
Cases/py 23/3933
HR (CI 95%)2 1.59 (1.24–2.03) 4 4 4 4 4 4
HR (CI 95%)3 1.98 (1.38–2.85) 4 4 4 4 4 4
All women
Cases/py 153/32,296 25/6,305 41/6,586 34/6,286 23/6,630 30/6,489
HR (CI 95%)2 0.99 (0.85–1.16) 1.00 (ref) 1.64 (0.98–2.74) 1.46 (0.86–2.49) 0.93 (0.52–1.67) 1.21 (0.70–2.09) 0.66
HR (CI 95%)3 0.92 (0.77–1.11) 1.00 (ref) 1.46 (0.85–2.49) 1.19 (0.67–2.12) 0.73 (0.39–1.37) 0.93 (0.50–1.73) 0.22
Never-smoking women
Cases/py 102/19,005 13/4,058 32/3,866 19/3,414 16/3,903 22/3,765
HR (CI 95%)2 1.08 (0.89–1.30) 1.00 (ref) 2.61 (1.34–5.08) 1.85 (0.90–3.83) 1.33 (0.63–2.81) 1.86 (0.92–3.76) 0.71
HR (CI 95%)3 1.01 (0.80–1.26) 1.00 (ref) 2.37 (1.19–4.73) 1.54 (0.72–3.29) 1.03 (0.46–2.31) 1.43 (0.68–3.02) 0.61
Diffuse large cell lymphoma
All men
Cases/py 159/28,981 32/5,656 28/5,661 35/5,899 34/5,833 30/5,933
HR (CI 95%)2 1.02 (0.90–1.17) 1.00 (ref) 0.89 (0.53–1.50) 1.12 (0.68–1.84) 1.12 (0.67–1.85) 0.93 (0.56–1.56) 0.94
HR (CI 95%)3 1.04 (0.91–1.20) 1.00 (ref) 0.93 (0.54–1.59) 1.23 (0.74–2.04) 1.26 (0.74–2.17) 1.06 (0.61–1.86) 0.73
Never-smoking men
Cases/py 19/3,933 4 4 4 4 4 4
All women
Cases/py 100/32,296 17/6,305 17/6,586 24/6,286 24/6,630 18/6,489
HR (CI 95%)2 0.98 (0.84–1.14) 1.00 (ref) 0.99 (0.50–1.98) 1.49 (0.78–2.84) 1.41 (0.73–2.69) 1.06 (0.54–2.09) 0.80
HR (CI 95%)3 1.02 (0.85–1.24) 1.00 (ref) 1.05 (0.51–2.15) 1.71 (0.87–3.36) 1.72 (0.84–3.50) 1.38 (0.63–3.02) 0.43
Never-smoking women
cases/py 64/19,005 17/6,063 28/6,306 19/6,636
HR (CI 95%)2 1.00 (0.81–1.22) 1.00 (ref) 1.67 (0.91–3.07) 1.05 (0.54–2.03) 0.73
HR (CI 95%)3 1.06 (0.83–1.36) 1.00 (ref) 1.79 (0.94–3.38) 1.27 (0.61–2.66) 0.94
Chronic lymphocytic leukemia
All men3
cases/py 134/28,981
HR (CI 95%)2 0.94 (0.81–1.09) 5 5 5 5 5 5
HR (CI 95%)3 0.88 (0.74–1.04) 5 5 5 5 5 5
Never-smoking men
cases/py 21/3,933
HR (CI 95%)2 1.04 (0.76–1.40) 4 4 4 4 4 4
HR (CI 95%)3 1.12 (0.82–1.54) 4 4 4 4 4 4
All women3
cases/py 66/32,296 24/9,743 19/11,168 23/11,385
HR (CI 95%)2 0.99 (0.71–1.10) 1.00 (ref) 0.74 (0.40–1.37) 0.85 (0.47–1.53) 0.74
HR (CI 95%)3 0.83 (0.64–1.09) 1.00 (ref) 0.74 (0.38–1.43) 0.81 (0.42–1.57) 0.70
Never-smoking women
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models with acrylamide as a continuous and categorical variable,
and mantle cell lymphoma, and T-cell lymphoma in models with
acrylamide as a continuous variable only. The numbers of other
subtypes were too small for separate analyses.
Besides age and sex, the following variables were tested to assess
potential confounding, based on the literature: body mass index
(BMI), height, non-occupational physical activity, education level,
vegetable and fruit intake, intake of several nutrients (such as fat
and saturated fat, trans fatty acids, carbohydrates, fiber and
niacin), alcohol consumption, smoking, reproductive factors (in
women only; age at menarche, menopause and first childbirth,
parity, and use of oral contraceptives and postmenopausal
hormone treatment), and immune system-related diseases self-
reported at baseline (such as hepatitis, tuberculosis and rheuma-
toid arthritis. Those variables that modified the hazard ratio of
acrylamide (with a unit of 27 mg/day: the interval between the 10th
and 90th percentile of acrylamide intake in the subcohort) by 10%
or more for any endpoint were used in the final multivariable-
adjusted model, which was subsequently applied to all endpoints.
Some variables were tested for interaction on the basis of their
ability to modify the activity of the enzyme CYP2E1. The
variables concerned are age, BMI, diabetes, physical activity, and
alcohol consumption [28,29].
Table 4. Association between continuously modeled dietary acrylamide intake (per 10 mg/d) and the risk of follicular lymphoma
and Waldenstrom macroglobulinemia and immunocytoma (WMI); the Netherlands Cohort Study on diet and cancer, 1986–2002.1
Follicular lymphoma
Waldenstro¨m
macroglobulinemia and
immunocytoma Mantle cell lymphoma T-cell lymphomas
All men
Cases/py 42/28,981 54/28,981 38/28,981 35/28,981
HR per 10 mg/d (CI 95%)1 1.20 (0.98–1.47) 1.18 (0.96–1.44) 0.96 (0.76–1.21) 0.94 (0.70–1.25)
HR per 10 mg/d (CI 95%)2 1.28 (1.03–1.61) 1.18 (0.93–1.50) 1.06 (0.85–1.31) 0.94 (0.68–1.29)
Never-smoking men
Cases/py 5/3,933 5/3,933 7/3,933 5/3,933
HR per 10 mg/d (CI 95%)1 3 3 3 3
HR per 10 mg/d (CI 95%)2 3 3 3 3
All women
Cases/py 47/32,296 35/32,296 18/32,296 19/32,296
HR per 10 mg/d (CI 95%)1 1.12 (0.83–1.51) 1.13 (0.85–1.50) 3 3
HR per 10 mg/d (CI 95%)2 1.12 (0.80–1.57) 1.21 (0.88–1.66) 3 3
Never-smoking women
Cases/py 27/19,005 20/19,005 9/19,005 12/19,005
HR per 10 mg/d (CI 95%)1 1.23 (0.91–1.67) 1.14 (0.78–1.68) 3 3
HR per 10 mg/d (CI 95%)2 1.18 (0.82–1.71) 1.27 (0.84–1.91) 3 3
HR = hazard ratio; CI = confidence interval; py = person years. The number of cases and person-years are the numbers that resulted after listwise deletion of
observations with missing values for the selected confounders. HRs were calculated by using Cox proportional hazards analysis.
1Adjusted for age and sex.
2Adjusted for age (years), sex, height (per 10 cm), education level, fiber (g/d), total fatty acids (g/d), trans unsaturated fatty acid (g/d), mono unsaturated fat (g/d), poly
unsaturated fat (g/d), carbohydrates (g/d) and niacin (mg/d).
3Insufficient number of cases for analyses with acrylamide as a continuous variable (N.20 requiered).
doi:10.1371/journal.pone.0038016.t004
Table 3. Cont.
Acrylamide
intake (per
10 mg/d) Q1/T1 Q2 Q3/T2 Q4 Q5/T3 P for trend
cases/py 45/19,005
HR (CI 95%)2 0.97 (0.75–1.25) 4 4 4 4 4 4
HR (CI 95%)3 0.95 (0.70–1.30) 4 4 4 4 4 4
1HR = hazard ratio; CI = Confidence Interval; py = person years; Q = quintile; T = tertile. The number of cases and person-years are the numbers that resulted after
listwise deletion of observations with missing values for the selected confounders. HRs were calculated by using Cox proportional hazards analysis.
2Adjusted for age and sex.
3Adjusted for age (years), sex, height (per 10 cm), education level, fiber (g/d), total fatty acids (g/d), trans unsaturated fatty acid (g/d), mono unsaturated fat (g/d), poly
unsaturated fat (g/d), carbohydrates (g/d) and niacin (mg/d).
4Insufficient number of cases for analyses with tertiles (N.60 required) or with acrylamide as a continuous variable (N.20 required).
5Proportional hazards assumption not met; therefore results not presented.
doi:10.1371/journal.pone.0038016.t003
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Table 5. Acrylamide hazard ratios (and 95% CI) of multiple myeloma, diffuse large cell lymphoma and chronic lymphatic leukemia
in men in strata of several covariables and p values for interaction: the Netherlands Cohort Study on diet and cancer, 1986–2002.
MM DLCL CLL
Interaction
variable
N cases/
person-
years
HR per
10 mg AA/d
P for
inter-
action
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-
years
HR per
10 mg AA/d
P for
Interaction
Smoking status
Never 23/3,933 1.92 (1.34–2.75) 0.02 19/3,933 1.03 (0.67–1.57) 0.05 21/3,933 1.06 (0.80–1.40) 0.45
Former 101/15,124 0.99 (0.82–1.19) 76/15,124 1.17 (0.97–1.42) 72/15,124 0.69 (0.53–0.90)
Current 46/9,925 1.18 (0.96–1.44) 64/9,925 0.90 (0.74–1.09) 41/9,925 1.04 (0.79–1.36)
Current smoking
Smoking quantity
(n cig./d)
0 23/3,933 1.92 (1.34–2.75) 0.03 19/3,933 1.03 (0.67–1.57) 0.64 21/3,933 1.06 (0.80–1.40) 0.77
0 to ,15 60/9,445 1.11 (0.92–1.34) 61/9,445 1.04 (0.85–1.28) 52/9,445 0.80 (0.62–1.03)
$15 82/13,935 1.04 (0.84–1.29) 73/13,935 1.13 (0.88–1.44) 52/13,935 0.86 (0.59–1.24)
Smoking duration
(y)
0 23/3,933 1.92 (1.34–2.75) 0.02 19/3,933 1.03 (0.67–1.57) 0.61 21/3,933 1.06 (0.80–1.40) 0.30
0 to ,30 56/8,513 1.00 (0.81–1.23) 48/8,513 1.04 (0.83–1.31) 39/8,513 0.60 (0.40–0.89)
.30 89/1,6117 1.12 (0.95–1.31) 91/16,117 1.06 (0.88–1.28) 73/16,117 0.97 (0.76–1.23)
Age
Ever and never-
smokers
55–59 58/11,922 1.03 (0.83–1.27) 0.48 50/11,922 0.93 (0.65–1.31) 0.07 43/11,922 0.96 (0.76–1.22) 0.37
60–64 64/10,059 1.23 (0.97–1.55) 62/10,059 1.24 (0.99–1.55) 50/10,059 0.81 (0.57–1.15)
65–69 48/7,000 1.19 (0.99–1.43) 47/7,000 0.84 (0.60–1.20) 41/7,000 0.83 (0.56–1.24)
Never-smokers
55–59 7/1,602 2 2 3 6/1,602 2 2
60–64 9/1,285 2 5/1,285 2
65–69 7/1,045 2 10/1,045 0.92 (0.42–2.01)
BMI (kg/m2)
Ever and never-
smokers
,20 2/520 2 2 2/520 2 2 4/520 2 2
$20–25 82/14,885 1.26 (1.10–1.44) 76/14,885 1.08 (0.90–1.29) 59/14,885 0.85 (0.66–1.10)
.25 85/13,380 0.88 (0.70–1.09) 79/13,380 1.03 (0.82–1.31) 70/13,380 0.91 (0.73–1.14)
Never-smokers
,20 0/64 2 2 3 1/64 2 2
$20–25 15/2,130 2.09 (1.43–3.05) 13/2,130 1.00 (0.59–1.70)
.25 7/1,706 2 7/1,706 2
Diabetes
Ever and never-
smokers
No 162/28,192 1.14 (1.02–1.29) 2 156/28,192 1.05 (0.91–1.21) 2 128/28,192 0.88 (0.74–1.04) 2
Yes 8/790 2 3/790 2 6/790 2
Never-smokers
No 22/3,840 1.94 (1.34–2.82) 2 3 20/3,840 1.14 (0.82–1.59) 2
Yes 1/93 2 1/93 2
Physical activity
(min/d)
Ever and never-
smokers
,30 26/4,503 1.11 (0.85–1.45) 0.85 38/4,503 0.84 (0.61–1.16) 0.40 29/4,503 0.72 (0.50–1.04) 0.57
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To test the proportional hazards assumption, models were run
using scaled Schoenfeld residuals. Hazard ratios and correspond-
ing 95% confidence intervals were obtained by performing Cox
proportional hazards regression using STATA software (version 9;
Stata Corp, College Station, TX) per subtype of lymphatic
malignancies for men and women separately. Standard errors
(SEs) were estimated by using the robust Huber-White sandwich
estimator to account for additional variance introduced by
sampling the subcohort from the cohort.
Smokers have on average three to four times higher levels of
acrylamide-hemoglobin adducts (which is a marker of internal
dose of acrylamide) than non-smokers. [30]. To preclude
confounding through the exposure of cigarette smoke, subgroup
analyses were performed for never-smokers.
Effect modification of the association between acrylamide intake
and cancer by other variables was tested using Wald chi-square
tests (by means of the testparm option in Stata). We thus tested
whether there were any statistically significantly differences in the
beta coefficients of acrylamide between the strata of the interaction
variable.
To assess whether observed associations could be attributed to
acrylamide intake or to the foods that contain the acrylamide, in
separate analyses, acrylamide hazard ratios were adjusted for the
five foods explaining most of the variance in acrylamide intake in
our population, namely Dutch spiced cake, coffee, cookies, potato
crisps and French fries.
All analyses were repeated without the first two years of follow-
up to investigate protopathic bias.
Results
The most outstanding differences between subcohort members
and cases were observed for physical activity and family history
between male subcohort members and male follicular lymphoma
cases, and family history between female subcohort members and
female mantle cell lymphoma cases (see table 2).
As described elsewhere, coffee was overall the biggest source of
acrylamide, but Dutch spiced cake was mainly responsible for the
variation in acrylamide intake, and next most responsible were
coffee, French fries, potato crisps, and cookies [31].
The hazard ratios for endpoints with more than 100 cases are
presented in table 3. For multiple myeloma, there was an
increased HR for the continuous acrylamide variable in all men
(smokers and non-smokers combined) (HR per 10 mg acrylamide/
day: 1.14; 95% CI: 1.01, 1.27), and a trend across the quintiles of
acrylamide intake (p for trend = 0.02). For never-smoking men,
the HR for the continuous acrylamide intake was increased as well
(HR per 10 mg acrylamide/day: 1.98; 95% CI: 1.38, 2.85).
Unfortunately, the limited number of cases in this subgroup
prohibited investigation of the dose-response relationship over
categories of acrylamide intake. No association with multiple
Table 5. Cont.
MM DLCL CLL
Interaction
variable
N cases/
person-
years
HR per
10 mg AA/d
P for
inter-
action
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-
years
HR per
10 mg AA/d
P for
Interaction
30–60 52/9,341 1.21 (0.94–1.56) 44/9,341 1.07 (0.84–1.36) 38/9,341 0.90 (0.65–1.24)
61–90 38/5,467 0.99 (0.75–1.31) 275,467 1.09 (0.67–1.76) 25/5,467 0.84 (0.50–1.41)
.90 53/9,203 1.14 (0.94–1.39) 48/9,203 1.13 (0.90–1.41) 40/9,203 0.98 (0.74–1.31)
Never-smokers
,30 3/656 2 2 3 4/656 2 2
30–60 9/1,116 2 6/1,116 2
61–90 5/873 2 3/873 2
.90 6/1,181 2 8/1,181 2
Alcohol intake (g/d)
Ever and never-
smokers
0 14/4,004 0.78 (0.34–1.77) 0.53 25/4,004 1.12 (0.93–1.34) 0.72 12/4,004 1.08 (0.69–1.71) 0.56
.0–5 46/6,084 1.29 (1.02–1.64) 34/6,084 1.01 (0.62–1.66) 35/6,084 0.92 (0.61–1.41)
.5 109/18,553 1.14 (0.98–1.33) 99/18,553 0.99 (0.82–1.20) 85/18,553 0.81 (0.65–1.01)
Never-smokers
0 2/874 2 2 3 2/874 2 2
.0–5 11/1,122 1.81 (1.17–2.80) 6/1,122 2
.5 10/1,921 2.28 (1.28–4.06) 13/1,921 0.96 (0.56–1.64)
Abbreviations: HR = hazard ratio; CI = confidence interval; AA/d = acrylamide per day, MM = multiple myeloma; CLL = chronic lymphatic leukemia; DLCL = diffuse
large cell lymphoma.
1Adjusted for age, sex, height (per 10 cm), education level, fiber (g/d), total fatty acids (g/d), trans unsaturated fatty acid (g/d), mono unsaturated fat (g/d), poly
unsaturated fat (g/d), carbohydrates (g/d) and niacin (mg/d).
2Insufficient number of cases for analyzing interaction.
3This subgroup was not analyzed at all, due to insufficient number of cases (n,20).
doi:10.1371/journal.pone.0038016.t005
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Table 6. Acrylamide hazard ratios (and 95% CI) of multiple myeloma, diffuse large cell lymphoma and chronic lymphatic leukemia
in women in strata of several covariables and p values for interaction: the Netherlands Cohort Study on diet and cancer, 1986–
2002.
MM DLCL CLL
Interaction
variable
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-years
HR per
10 mg AA/d
P for
interaction
Smoking status
Never 102/19,005 1.02 (0.80–1.26) 0.24 64/19,005 1.06 (0.83–1.36) 0.36 45/19,005 0.93 (0.68–1.27) 2
Former 33/6,716 0.74 (0.49–1.12) 18/6,716 1.29 (0.86–1.91) 13/6,716 0.72 (0.41–1.28)
Current 18/6,574 0.67 (0.31–1.44) 18/6,574 0.49 (0.19–1.24) 8/6,574 2
Current smoking
Smoking quantity (n
cig./d)
0 102/19,005 1.01 (0.80–1.26) 0.23 64/19,005 1.06 (0.83–1.36) 0.83 45/19,005 0.93 (0.68–1.27) 2
0 to ,15 37/8,238 0.63 (0.39–1.02) 24/8,238 1.06 (0.72–1.55) 11/8,238 0.79 (0.44–1.41)
$15 14/4,501 0.94 (0.49–1.83) 12/4,501 0.83 (0.50–1.36) 9/4,501 2
Smoking duration (y)
0 102/19,005 1.01 (0.80–1.26) 0.18 64/19,005 1.06 (0.83–1.36) 0.83 45/19,005 0.93 (0.68–1.27) 2
0 to ,30 28/6,405 0.66 (0.39–1.12) 15/6,405 1.05 (0.60–1.87) 9/6,405 2
$30 22/6,530 0.79 (0.42–1.49) 21/6,530 0.98 (0.64–1.50) 11/6,530 0.66 (0.31–1.43)
Age
Ever and never-
smokers
55–59 43/13,090 0.89 (0.68–1.16) 0.66 36/13,090 1.03 (0.76–1.38) 0.14 17/13,090 0.44 (0.16–1.23) 0.27
60–64 57/10,768 1.00 (0.74–1.36) 29/10,768 1.41 (0.96–2.07) 23/10,768 0.96 (0.62–1.49)
65–69 53/8,437 0.88 (0.60–1.30) 35/8,437 0.77 (0.56–1.06) 26/8,437 0.96 (0.70–1.32)
Never-smokers
55–59 27/6,852 0.90 (0.67–1.22) 0.87 20/6,852 1.05 (0.74–1.51) 0.22 6/6,852 2 2
60–64 38/6,424 0.99 (0.65–1.52) 18/6,424 1.35 (0.82–2.22) 17/6,424 0.80 (0.45–1.42)
65–69 37/5,729 1.13 (0.73–1.74) 26/5,729 0.82 (0.56–1.21) 22/5,729 1.01 (0.69–1.49)
BMI (kg/m2)
Ever and never-
smokers
,20 4/1,520 2 2 4/1,520 2 2 9/1,520 2 2
$20–25 66/16,362 0.83 (0.61–1.14) 51/16,362 1.03 (0.79–1.35) 30/16,362 0.67 (0.41–1.09)
.25 80/14,279 1.04 (0.81–1.32) 45/14,279 1.04 (0.78–1.38) 27/14,279 0.99 (0.68–1.45)
Never-smokers
,20 1/658 2 2 1/658 2 2 5/658 2 2
$20–25 42/9,189 0.91 (0.60–1.37) 33/9,189 1.03 (0.71–1.51) 19/9,189 0.81 (0.43–1.52)
.25 58/9,119 1.11 (0.85–1.45) 30/9,119 1.04 (0.76–1.43) 21/9,119 1.12 (0.75–1.69)
Diabetes
Ever and never-
smokers
No 148/31,252 0.90 (0.75–1.07) 2 97/31,252 1.03 (0.85–1.25) 2 63/31,252 0.84 (0.64–1.11) 2
Yes 5/1,044 2 3//1,044 2 3/1,044 2
Never-smokers
No 98/18,264 0.96 (0.77–1.19) 2 63/18,264 1.06 (0.82–1.37) 2 42/18,264 0.97 (0.71–1.34) 2
Yes 4/742 2 1/742 2 3/742 2
Physical activity
(min/d)
Ever and never-
smokers
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myeloma was observed in women, except for an increased HR in
the 2nd quintile in never-smoking women.
Acrylamide was not associated with diffuse large cell lymphoma
in any of the subgroups of men, women, or never-smoking men
and women.
We observed decreased risks of chronic lymphocytic leukemia in
both men and women for acrylamide as a continuous variable. In
the subgroup of men, the proportional hazards assumption was
violated in the quintile analysis. When we split the follow-up time
at 2 years, at 8 years, or at 5 and 10 years, no clear associations
between acrylamide intake and CLL risk in men were observed.
For instance, in the first 8 years of follow-up, the hazard ratios for
tertiles of acrylamide intake were 0.85 (95% CI: 045–1.63) and
0.80 (95% CI: 0.41–1.55) for the 2nd and 3rd tertile, respectively,
with a p-trend of 0.50 (n = 53). In the last 8.3 years the
corresponding values were 1.10 (95% CI: 0.61–1.99) and 0.67
(0.34–1.31), with a p-trend of 0.19 (n = 81). No association was
seen in never-smokers.
Table 4 shows the hazard ratios for the continuous acrylamide
variable for endpoints with less than 100 cases. The HR for
acrylamide as a continuous variable for follicular lymphoma in all
men was increased (HR per 10 mg acrylamide/day: 1.28; 95% CI:
1.03, 1.61), but not in all or never-smoking women.
We did not observe associations between acrylamide intake and
the risk of Waldenstro¨m macroglobulinemia and immunocytoma
in men or in women, or mantle cell lymphoma or T-cell-
lymphoma in men. There were too few women in these latter two
groups for meaningful analyses.
The results of the analyses of interactions between acrylamide
and possible CYP2E1-influencing variables are presented in table 5
(men) and 6 (women) for multiple myeloma, diffuse large cell
lymphoma and chronic lymphocytic leukemia. The numbers for
other subtypes were too small for analysis of interaction.
In the analyses of multiple myeloma, smoking status modified
the acrylamide-associated risk in men. Never-smokers had a
higher acrylamide-associated risk of multiple myeloma (HR per
10 mg acrylamide/day: 1.92 (95% CI: 1.34, 2.75; p for interaction
= 0.02)) than former or current smokers, which was also reflected
by the interaction with smoking quantity and duration. Although
there was no statistically significant interaction with alcohol, we
observed an increased acrylamide-associated risk of multiple
myeloma in never-smoking men with the highest (.5 g/day)
intake of alcohol (HR 2.28 (95% CI: 1.28, 4.06) For diffuse large
cell lymphoma, smoking status modified the acrylamide-associated
risk in men, with former smokers having the highest acrylamide-
associated risk (HR per 10 mg acrylamide/day: 1.17 (95% CI:
0.97, 1.42); p for interaction = 0.05), but not in women (p for
interaction = 0.36).
For chronic lymphocytic leukemia, there was no interaction
between acrylamide intake and any of the CYP2E1-influencing
variables.
In sensitivity analyses, the associations between acrylamide and
the endpoints of lymphatic malignancies did not change after
Table 6. Cont.
MM DLCL CLL
Interaction
variable
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-
years
HR per
10 mg AA/d
P for
interaction
N cases/
person-years
HR per
10 mg AA/d
P for
interaction
,30 34/7,170 0.54 (0.35–0.83) 0.42 26/7,170 1.16 (0.86–1.58) 0.47 15/7,170 0.74 (0.45–1.22) 0.16
30–60 52/9,977 1.07 (0.79–1.45) 30/9,977 1.12 (0.82–1.53) 22/9,977 0.90 (0.57–1.43)
61–90 32/7,236 1.01 (0.71–1.43) 21/7,236 0.95 (0.59–1.53) 16/7,236 0.75 (0.39–1.44)
.90 31/7,089 1.10 (0.69–1.77) 21/7,089 0.78 (0.52–1.16) 13/7,089 1.05 (0.58–1.89)
Never-smokers
,30 23/4,493 0.49 (0.25–0.95) 0.26 15/4,493 1.24 (0.82–1.86) 0.83 12/4,493 0.79 (0.43–1.45) 2
30–60 36/6,215 1.36 (0.97–1.90) 21/6,215 1.17 (0.81–1.71) 15/6,215 1.10 (0.68–1.77)
61–90 21/3,784 1.06 (0.71–1.57) 15/3,784 0.70 (0.31–1.57) 11/3,784 1.10 (0.58–2.09)
.90 20/3,948 1.03 (0.51–2.09) 12/3,948 0.92 (0.54–1.55) 7/3,948 2
Alcohol intake (g/d)
Ever and never-
smokers
0 40/9,793 0.92 (0.67–1.28) 0.81 35/9,793 1.01 (0.72–1.41) 0.62 21/9,793 0.89 (0.56–1.39) 0.69
.0–5 65/11,351 0.95 (0.69–1.32) 45/11,351 0.98 (0.72–1.35) 21/11,351 0.60 (0.37–0.97)
.5 39/9,812 0.94 (0.66–1.34) 18/9,812 1.15 (0.84–1.59) 21/9,812 1.00 (0.62–1.63)
Never-smokers
0 28/6,975 0.88 (0.59–1.31) 0.78 21/6,975 0.76 (0.46–1.26) 2 18/6,975 0.91 (0.52–1.57) 2
.0–5 51/7,410 1.13 (0.79–1.61) 33/7,410 1.21 (0.84–1.74) 16/7,410 0.62 (0.36–1.06)
.5 17/3,692 1.05 (0.62–1.77) 8/3,692 2 8/3,692 2
Abbreviations: HR = hazard ratio; CI = confidence interval; AA/d = acrylamide per day, MM = multiple myeloma; CLL = chronic lymphatic leukemia; DLCL = diffuse
large cell lymphoma.
1Adjusted for age, sex, height (per 10 cm), education level, fiber (g/d), total fatty acids (g/d), trans unsaturated fatty acid (g/d), mono unsaturated fat (g/d), poly
unsaturated fat (g/d), carbohydrates (g/d) and niacin (mg/d).
2Insufficient number of cases.
doi:10.1371/journal.pone.0038016.t006
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exclusion of cases diagnosed during the first two years of follow-up.
Although the HRs of acrylamide intake were slightly attenuated
after additional adjustment for coffee, and increased after
adjustment for Dutch spiced cake, the results did not change
importantly. The results also did not change when adjusted for the
other foods that contribute most to the variance in acrylamide
intake, which were cookies, French fries and potato crisps. All of
these foods were themselves not associated with the risk of
lymphatic malignancies (results not shown).
At the time of the analyses described in this paper, our data on
lymphatic malignancies were not classified according to the
InterLymph classification [32]. We have checked how our
classification of the cases corresponds to the InterLymph
classification for the types of lymphatic malignancies that we
observed associations with acrylamide for (multiple myeloma and
follicular lymphoma in men). There were no (multiple myeloma)
or minor differences (n = 1 for follicular lymphoma) between the
two classifications. When we left out the male case that was a
follicular lymphoma case in our dataset, but that would have been
a chronic/small lymphocytic leukemia/lymphoma case in the
InterLymph classification, the hazard ratios for acrylamide were
virtually unchanged. A major difference between the WHO
classification and the InterLymph classification lies in the way
lymphomas with morphology code M9675 are classified. In the
WHO classification, they are grouped under diffuse large cell
lymphoma, but not all M9675 lymphomas are large cell
lymphomas and some are T-cell lymphomas. We have repeated
the analysis of the diffuse large cell lymphoma group excluding the
M9675 codes (n = 27 men, 12 women) (which then renders the
group of diffuse large B-cell lymphomas according to the
InterLymph recommendations) and the results were essentially
unchanged.
Discussion
This prospective cohort study is, to our knowledge, the first
epidemiological study to investigate the association between
dietary acrylamide intake and the risk of specific histological
subtypes of lymphatic malignancies. Because of this, the results of
this study are challenging, but should be interpreted cautiously.
We observed a positive association for multiple myeloma in all
men and never-smoking men, and for follicular lymphoma in all
men.
In the Finnish ATBC Study, no association was observed
between dietary acrylamide intake and the risk of lymphomas in
male smokers [17]. In that study, no analyses were done for
histological subtypes of lymphatic malignancies, and therefore an
association with a specific type of lymphatic malignancy might
have been obscured. In addition, when studying the link between
dietary acrylamide intake and cancer risk, it is better to study non-
smokers as a subgroup, because cigarette smoke is a much more
important source of acrylamide than diet is and it might therefore
blur the association between acrylamide through diet and cancer
risk.
Possible risk factors for lymphatic malignancies, such as height,
overweight, hormones and nutrients, have shown contradictory
results in epidemiological studies [20,25]. Although there is thus
no strong epidemiological evidence for risk factors for lymphatic
malignancies, in the present study we checked the confounding
potential of a broad range of possible risk factors for lymphatic
malignancies and cancer in general. Human immunodeficiency
virus (HIV) infection has been associated with an increased risk of
lymphatic malignancies [20]. Data on the prevalence of HIV in
our study population was not available, but the prevalence was
likely low, considering the age segment of our population. We
were able to check for other immune system-related diseases, such
as asthma and tuberculosis, but these diseases were not found to be
confounders for the association between acrylamide intake and the
risk of lymphatic malignancies.
The present study has some limitations that should be discussed.
The associations between dietary acrylamide intake and multiple
myeloma in never-smoking men, and the association for follicular
lymphoma in all men were based on analyses with a small number
of cases. This makes it likely that some of the observed associations
are spurious. Therefore, these results should be interpreted
cautiously. Moreover, we analyzed associations in many subtypes
of lymphatic malignancies and for several subgroups within each
subtype, which makes it likely that chance findings have occurred.
The same applies to the subgroup analyses that were done to
investigate interaction with CYP2E1-influencing variables. How-
ever, the indications for possible interaction with smoking and
alcohol are intriguing, although based on analyses with a small
number of cases, as both smoking and alcohol intake were
inversely associated with the glycidamide to acrylamide hemoglo-
bin adduct ratio in a cross-sectional population study [33].
In addition, this study has some limitations regarding acrylam-
ide intake assessment. Firstly, within foods, acrylamide levels vary
greatly, which leads to non-differential misclassification of
acrylamide intake when assigning a single mean acrylamide value
to a food, which most likely biases risk estimates towards null. This
means that true risks, if any, are probably greater than the risks
presented here. Moreover, a recent study has shown that it is
feasible to make a sound rank ordering of the acrylamide intake
via a 24-hour meal using the mean acrylamide levels used in the
NLCS study for individual foods. [27]. Secondly, the acrylamide
values in our food database were derived from foods that were
sampled in 2002 and 2005. They may not be completely
representative of the foods that were on the market in 1986.
Thirdly, the FFQ did not provide information on which foods
were prepared at home and how this was done. Both aspects too
will have resulted in some non-differential misclassification of the
intake, which will then most likely have led to underestimation of
the true risks. Despite the fact that the use of an FFQ has
limitations for the assessment of dietary acrylamide exposure, as is
extensively discussed elsewhere [34], it is the only feasible way to
assess dietary acrylamide intake over a long period of time in a
large study population.
Although we have no direct data for acrylamide itself, the
reproducibility and validity of the NLCS FFQ for acrylamide can
to some extent be derived from nutrients that are correlated to
acrylamide, namely carbohydrates and dietary fiber. The decline
of the correlation between the baseline questionnaire and the
questionnaire administered after 5 years of follow-up was 0.07 on
average among the nutrients that were tested. This indicates that,
although the questionnaire was administered only once, it
characterizes long-term food intake for over a period of at least
five years [35]. As for validity, the correlation coefficients between
the FFQ and a dietary record method were 0.77 for carbohydrates
and 0.74 for fiber. For the food groups potatoes, bread, and cakes
and cookies, Spearman correlation coefficients were 0.74, 0.80 and
0.65, respectively [36].
The large study size and the prospective nature of this NLCS
are important strengths of this study. Selection bias is unlikely to
occur, as the follow-up of the participants was complete. Due to
the prospective design of the study, recall bias is absent. In
addition, we were able to obtain a dietary acrylamide intake
estimate representative for the Dutch study population, by
estimating acrylamide levels in several batches of various Dutch
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food products that were specific for the population under study.
The large study size enabled us to study specific histological
subtypes of lymphatic malignancies that differ in their etiology
and, as indicated by this study, may differ regarding their
association with dietary acrylamide intake.
Recent analyses within the NLCS, the Nurses’ Health Study,
and a Danish cohort study [11,12,13,14] showed a positive
association for endometrial, ovarian, and estrogen receptor-
positive breast cancer, suggesting that disturbance of sex hormonal
balances may be a mechanism of acrylamide carcinogenesis, which
can also be suggested based on the rat carcinogenicity assays [7,8].
Although it cannot be concluded from the present study, hormonal
imbalances might be a mechanism of acrylamide carcinogenesis
for lymphatic malignancies as well. Men have a higher incidence
of lymphatic malignancies than women [20], but the reasons for
this higher incidence are not known. Sex hormones have been
shown to influence the immune system [37] and may thus be at the
basis of this observed difference. Estrogen receptor expression in
lymphocytes suggests that estrogen bioavailability may be relevant
to the pathogenesis of lymphomas [38]. For multiple myeloma,
studies investigated the mechanism of anti-estrogens (AEs), and
showed that AEs inhibit cell cycle progression of malignant
multiple myeloma cells and/or induce apoptosis in these cells [39].
Other studies suggest that hormone-related and reproductive
factors are involved in the etiology of lymphatic malignancies
[40,41,42], and in a different way for men and women [43], but
the results are inconsistent.
This is the first epidemiological study to investigate the
association between dietary acrylamide intake and the risk of
lymphatic malignancies. It provides indications that acrylamide
may increase the risk of multiple myeloma and follicular
lymphoma, but on the basis of the present study alone, we cannot
conclude whether these results reflect true biological effects or are
chance findings. We recommend that this possible modifiable risk
factor for lymphatic malignancies is investigated in other
prospective studies.
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